keyword
https://read.qxmd.com/read/38732416/-arbutus-unedo-l-fractions-exhibit-chemotherapeutic-properties-for-the-treatment-of-gastrointestinal-stromal-tumors
#1
JOURNAL ARTICLE
Aldo Di Vito, Manuela Mandrone, Ilaria Chiocchio, Francesca Gorini, Gloria Ravegnini, Emma Coschina, Eva Benuzzi, Simona Trincia, Augusto Hubaide Nozella, Trond Aasen, Cinzia Sanna, Fabiana Morroni, Patrizia Hrelia, Ferruccio Poli, Sabrina Angelini
Novel treatments in gastrointestinal stromal tumors (GISTs) are essential due to imatinib resistance and the modest results obtained with multi-target tyrosine kinase inhibitors. We investigated the possibility that the hydroalcoholic extract from the leaves of Arbutus unedo L. (AUN) could harbor novel chemotherapeutics. The bio-guided fractionation of AUN led to a subfraction, FR2-A, that affected the viability of both imatinib-sensitive and -resistant GIST cells. Cells treated with FR2-A were positive for Annexin V staining, a marker of apoptosis...
April 25, 2024: Plants (Basel, Switzerland)
https://read.qxmd.com/read/38732067/plexiform-fibromyxoma-in-the-stomach-immunohistochemical-profile-and-comprehensive-genetic-characterization
#2
JOURNAL ARTICLE
Annabella Di Mauro, Rosalia Anna Rega, Maddalena Leongito, Vittorio Albino, Raffaele Palaia, Alberto Gualandi, Andrea Belli, Imma D'Arbitrio, Pasquale Moccia, Salvatore Tafuto, Annarosaria De Chiara, Alessandro Ottaiano, Gerardo Ferrara
Plexiform fibromyxoma (PF), also referred to as plexiform angiomyxoid myofibroblast tumor, is an exceedingly rare mesenchymal neoplasm primarily affecting the stomach. Herein, we present a case of PF diagnosed in a 71-year-old male with a history of lung cancer, initially suspected to have a gastrointestinal stromal tumor (GIST) of the stomach, who subsequently underwent subtotal gastrectomy. The histopathological and molecular features of the tumor, including mutations in ABL1 , CCND1 , CSF1R , FGFR4 , KDR , and MALAT1-GLI1 fusion, are elucidated and discussed in the context of diagnostic, prognostic, and therapeutic considerations...
April 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38730662/utility-of-clinical-next-generation-sequencing-tests-in-kit-pdgfra-sdh-wild-type-gastrointestinal-stromal-tumors
#3
JOURNAL ARTICLE
Ryan A Denu, Cissimol P Joseph, Elizabeth S Urquiola, Precious S Byrd, Richard K Yang, Ravin Ratan, Maria Alejandra Zarzour, Anthony P Conley, Dejka M Araujo, Vinod Ravi, Elise F Nassif Haddad, Michael S Nakazawa, Shreyaskumar Patel, Wei-Lien Wang, Alexander J Lazar, Neeta Somaiah
Objective: The vast majority of gastrointestinal stromal tumors (GISTs) are driven by activating mutations in KIT , PDGFRA , or components of the succinate dehydrogenase (SDH) complex ( SDHA , SDHB , SDHC , and SDHD genes). A small fraction of GISTs lack alterations in KIT , PDGFRA , and SDH . We aimed to further characterize the clinical and genomic characteristics of these so-called "triple-negative" GISTs. Methods: We extracted clinical and genomic data from patients seen at MD Anderson Cancer Center with a diagnosis of GIST and available clinical next generation sequencing data to identify "triple-negative" patients...
April 27, 2024: Cancers
https://read.qxmd.com/read/38730621/germline-genetic-mutations-in-adult-patients-with-sarcoma-insight-into-the-middle-east-genetic-landscape
#4
JOURNAL ARTICLE
Ramiz Abu-Hijlih, Baha Sharaf, Samer Salah, Hira Bani Hani, Mohammad Alqaisieh, Abdulla Alzibdeh, Layan Ababneh, Suleiman Mahafdah, Hikmat Abdel-Razeq
Data on germline mutations in soft tissue and bone sarcomas are scarce. We sought to identify the prevalence of germline mutations in adult sarcoma patients treated at a tertiary cancer center. Newly diagnosed patients were offered germline genetic testing via an 84-gene panel. The prevalence of pathogenic germline variants (PGVs) and their association with disease-, and patient- related factors are reported. A total of 87 patients were enrolled, the median age was 48 (19-78) years, and 47 (54%) were females...
April 25, 2024: Cancers
https://read.qxmd.com/read/38728971/a-case-report-peritonitis-secondary-to-perforated-locally-advanced-gastrointestinal-stromal-tumor
#5
Hager Behi, Ahmed Omry, Hanene Guelmami, Amel Changuel, Amal Kamtaoui, Med Bachir Khalifa
INTRODUCTION AND IMPORTANCE: Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms predominantly affecting the gastrointestinal tract. While they often remain asymptomatic, GISTs can lead to acute abdominal emergencies, such as peritonitis secondary to tumor perforation, a rare yet serious complication. Here, we present a unique case of a locally advanced ileal gastrointestinal stromal tumor complicated by generalized purulent peritonitis, emphasizing the diagnostic and management challenges associated with this condition...
May 9, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38726808/monitoring-advanced-gastrointestinal-stromal-tumor-with-circulating-tumor-dna
#6
JOURNAL ARTICLE
David Gómez-Peregrina, Carlo Maria Cicala, César Serrano
PURPOSE OF REVIEW: This review explores the role of circulating tumor (ct)DNA as a biomarker for clinical decision-making and monitoring purposes in metastatic gastrointestinal stromal tumor (GIST) patients. We discuss key insights from recent clinical trials and anticipate the future perspectives of ctDNA profiling within the clinical landscape of GIST. RECENT FINDINGS: The identification and molecular characterization of KIT/platelet-derived growth factor receptor alpha (PDGFRA) mutations from ctDNA in metastatic GIST is feasible and reliable...
April 22, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38725399/endoscopic-resection-penetrating-the-muscularis-propria-for-gastric-gastrointestinal-stromal-tumors-advances-and-challenges
#7
EDITORIAL
Jin Woong Cho
No abstract text is available yet for this article.
May 10, 2024: Clinical Endoscopy
https://read.qxmd.com/read/38721407/images-in-immunotherapy-and-precision-oncology-a-case-report-of-neurofibromatosis-1
#8
Anagha Deshpande, Javier Munoz, Vrushali Dabak, Amr Hanbali, Razelle Kurzrock
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that primarily causes the growth of tumors along nerves. Additionally, the germline mutations involved in NF1 predispose patients to develop further malignancies. The mainstay initial treatment for these malignancies is surgical removal at diagnosis, although targeted therapies are under evaluation in the relapsed setting. We report a case of malignant peripheral nerve sheath tumor (MPNST), gastrointestinal stromal tumor (GIST), and pheochromocytoma in a patient with NF1 who presented with an infected right shoulder lesion that was confirmed to be spindle cell sarcoma via biopsy...
May 2024: Journal of immunotherapy and precision oncology
https://read.qxmd.com/read/38720315/short-term-and-long-term-outcomes-after-robotic-radical-surgery-for-rectal-gastrointestinal-stromal-tumor
#9
JOURNAL ARTICLE
Chikara Maeda, Yusuke Yamaoka, Akio Shiomi, Hiroyasu Kagawa, Hitoshi Hino, Shoichi Manabe, Chen Kai, Kenji Nanishi
BACKGROUND: The optimal approach for ensuring both complete resection and preservation of anal function in rectal gastrointestinal stromal tumor (GIST) remains unknown. The aim of this study was to clarify short-term and long-term outcomes after robotic radical surgery for rectal GIST. METHODS: A total of 13 patients who underwent robotic radical surgery for rectal GIST between December 2011 and April 2022 were included. All robotic procedures were performed using a systematic approach...
May 9, 2024: BMC Surgery
https://read.qxmd.com/read/38715791/microwave-ablation-for-painful-chest-wall-metastases-from-gastrointestinal-stromal-tumor-a-case-report
#10
Shishi Wang, Lu Wang, Tingting Li, Yuan Li, Min Zhuang, Man Lu
BACKGROUND: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the digestive tract, with the potential to metastasize. Metastases to bone and soft tissue are more frequent in advanced cases, where targeted therapy is the standard treatment. However, around 10-15% of patients develop disease progression despite treatment. Studies have shown the efficacy of ablation in managing bone and soft tissue metastases (1, 2), but there are no reports of ablation for treating GIST bone or soft tissue metastases...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38712513/discontinuation-of-imatinib-in-patients-with-oligometastatic-gastrointestinal-stromal-tumour-who-are-in-complete-radiological-remission-a-prospective-multicentre-phase-ii-study
#11
MULTICENTER STUDY
Ivar Hompland, Kjetil Boye, Anne Marit Wiedswang, Andri Papakonstantinou, Bård Røsok, Heikki Joensuu, Øyvind Bruland
INTRODUCTION: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kinase inhibitors is recommended. We investigated whether selected patients with metastatic GIST may remain in durable remission despite imatinib discontinuation. PATIENTS: In this 1-group, prospective, multicentre phase II trial selected patients with oligometastatic (≤3 metastases) GIST discontinued imatinib treatment. Eligible patients had been treated with imatinib >5 years without progression and had no radiologically detectable metastases after metastasectomy, radiofrequency ablation (RFA) or complete response to imatinib...
May 7, 2024: Acta Oncologica
https://read.qxmd.com/read/38709670/the-world-health-organization-reporting-system-for-pancreaticobiliary-cytopathology-overview-and-summary
#12
REVIEW
Barbara A Centeno, Mauro Saieg, Momin T Siddiqui, Miguel Perez-Machado, Lester J Layfield, Birgit Weynand, Michelle D Reid, Edward B Stelow, Maria D Lozano, Noriyoshi Fukushima, Ian A Cree, Ravi Mehrotra, Fernando C Schmitt, Andrew S Field, Martha B Pitman
The recently published WHO Reporting System for Pancreaticobiliary Cytopathology (World Health Organization [WHO] System) is an international approach to the standardized reporting of pancreaticobiliary cytopathology, updating the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSC System). Significant changes were made to the categorization of benign neoplasms, intraductal neoplasms, mucinous cystic neoplasms, and malignant neoplasms considered low grade. Benign neoplasms, such as serous cystadenoma, categorized as Neoplastic: benign in the PSC system, are categorized as Benign/negative for malignancy in the WHO system...
May 6, 2024: Cancer Cytopathology
https://read.qxmd.com/read/38707060/schwann-cell-hamartoma-presenting-as-a-colonic-polyp-a-rare-case-report-with-a-literature-review
#13
Faryal Altaf, Nismat Javed, Haider Ghazanfar, Anil Dev
Mucosal Schwann cell hamartomas (MSCHs) are non-common noncancerous growths derived from Schwann cells in the peripheral nervous system, often found unexpectedly during routine colonoscopy examinations. These growths primarily occur in the colon, although they can also appear in the esophagus and are not linked to familial cancer syndromes. Diagnosis relies on specific histological characteristics and staining patterns. It is essential to distinguish MSCHs accurately since their appearance can closely resemble that of malignant tumors...
April 2024: Curēus
https://read.qxmd.com/read/38704586/mature-cystic-teratoma-with-co-existent-mucinous-cystadenocarcinoma-describing-a-diagnostic-challenge-a-case-report
#14
JOURNAL ARTICLE
Mahboobeh Chahkandi, Farnaz Mozayani, Ali Fanoodi, Amir Reza Bina, Amir Reza Ebrahimian
BACKGROUND: Mature cystic teratoma co-existing with a mucinous cystadenocarcinoma is a rare tumor that few cases have been reported until now. In these cases, either a benign teratoma is malignantly transformed into adenocarcinoma or a collision tumor is formed between a mature cystic teratoma and a mucinous tumor, which is either primarily originated from epithelial-stromal surface of the ovary, or secondary to a primary gastrointestinal tract tumor. The significance of individualizing the two tumors has a remarkable effect on further therapeutic management...
May 5, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38699682/safety-outcomes-of-low-versus-high-dose-imatinib-mesylate-in-patients-with-advanced-metastatic-or-nonresectable-gastrointestinal-stromal-tumors-a-systematic-review
#15
JOURNAL ARTICLE
Marena A Marucci, Doreen W Lechner, Barbara A Tafuto
BACKGROUND AND OBJECTIVES: Gastrointestinal stromal tumors (GIST) are a rare cancer where tumors grow along the gastrointestinal tract. While treatment options aim towards surgical resection, some patients present with advanced metastatic and/or nonresectable diseases. The tyrosine kinase inhibitor imatinib mesylate is approved for this indication. However, dose escalation from 400 to 600 mg/d or 800 mg/d is allowed. The present study systematically evaluates the safety outcomes, particularly the incidence of grade ⩾ 3 adverse events (AEs) with low dose compared with high dose imatinib in these patients...
2024: Gastrointest Tract
https://read.qxmd.com/read/38698259/clinical-outcomes-of-endoscopic-resection-for-the-treatment-of-intermediate-or-high-risk-gastric-small-gastrointestinal-stromal-tumors-a-multicenter-retrospective-study
#16
JOURNAL ARTICLE
Enpan Xu, Qiang Shi, Zhipeng Qi, Bing Li, Huihui Sun, Zhong Ren, Shilun Cai, Dongli He, Zhengtao Lv, Zhanghan Chen, Liang Zhong, Leiming Xu, Xiaobo Li, Shuchang Xu, Pinghong Zhou, Yunshi Zhong
BACKGROUND AND AIMS: Many studies of gastric gastrointestinal stromal tumors (g-GISTs) following endoscopic resection (ER) have typically focused on tumor size, with most tumors at low risk of aggressiveness after risk stratification. There have been few systematic studies on the oncologic outcomes of intermediate- or high-risk g-GISTs after ER. METHODS: From January 2014 to January 2020, we retrospectively collected patients considered at intermediate- or high-risk of g-GISTs according to the modified NIH consensus classification system...
May 2, 2024: Surgical Endoscopy
https://read.qxmd.com/read/38694323/leiomyosarcoma-of-stomach-extending-to-gastroesophageal-junction-and-distal-esophagus-as-a-rare-cause-of-dysphagia-a-case-report
#17
Lilamani Rajthala, Sagar Gyawali, Sabin Banmala, Surendra Shah
INTRODUCTION AND IMPORTANCE: Gastric leiomyosarcoma is a rare malignant tumor among the primary gastric carcinomas. Among the different common presentations, dysphagia is an uncommon presentation of gastric leiomyosarcoma. CASE PRESENTATION: A 29-year-old female presented with complaints of progressive dysphagia for 1 year associated with vomiting, significant weight loss, and anorexia for 6 months. On blood investigations, she had anemia, hypokalemia, prerenal acute kidney injury, and unconjugated hyperbilirubinemia...
May 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38691132/non-gastrointestinal-stromal-tumor-mesenchymal-neoplasms-of-the-gastrointestinal-tract-a-review-of-tumor-genetics-pathology-and-cross-sectional-imaging-findings
#18
REVIEW
Aditya S Prasad, Krishna P Shanbhogue, Nisha S Ramani, Rashmi Balasubramanya, Venkateswar R Surabhi
There is a diverse group of non-gastrointestinal stromal tumor (GIST), mesenchymal neoplasms of the gastrointestinal (GI) tract that demonstrate characteristic pathology and histogenesis as well as variable imaging findings and biological behavior. Recent advancements in tumor genetics have unveiled specific abnormalities associated with certain tumors, influencing their molecular pathogenesis, biology, response to treatment, and prognosis. Notably, giant fibrovascular polyps of the esophagus, identified through MDM2 gene amplifications, are now classified as liposarcomas...
May 1, 2024: Abdominal Radiology
https://read.qxmd.com/read/38690828/a-rare-clinical-case-of-extra-gastrointestinal-stromal-pancreatic-tumor
#19
JOURNAL ARTICLE
Alexey Shabunin, Zurab Bagatelia, Mikhail Tavobilov, David Dolidze, Igor Andreytsev, Tatiana Sheviakova, Nataliya Ivanova, Anna Foshina, Zarui Chibukhchyan, Serghei Covantsev
Extra-gastrointestinal stromal tumors arising from the pancreas are extremely rare. To date, just over 30 cases have been described in the world literature. A clinical observation of a 67-year-old patient with dull epigastric pain and a large cystic solid neoplasm instrumentally identified as an extra-gastrointestinal stromal tumor of the head of the pancreas is presented. The volume of surgical intervention consisted of pancreatogastroduodenectomy and right-sided hemicolectomy, since tumor invasion into the transverse mesocolon was detected intraoperatively...
April 30, 2024: Folia Medica
https://read.qxmd.com/read/38689248/comparison-of-outcomes-between-early-stage-cervical-cancer-patients-without-high-risk-factors-undergoing-adjuvant-concurrent-chemoradiotherapy-and-radiotherapy-alone-after-radical-surgery
#20
COMPARATIVE STUDY
Yuncan Zhou, Weiping Wang, Jia Tang, Ke Hu, Fuquan Zhang
PURPOSE: For patients with early-stage cervical cancer without high-risk factors, there is no consensus regarding the optimal postoperative treatment regimen and whether postoperative concurrent radiochemotherapy (CCRT) is superior to radiotherapy (RT) alone. PATIENTS AND METHODS: The medical records of patients with stage I-IIA cervical cancer, who underwent radical surgery and postoperative RT or CCRT between June 2012 and December 2017, were retrospectively reviewed...
April 30, 2024: BMC Cancer
keyword
keyword
31676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.